A conditional model predicting the 10-year annual extra mortality risk compared to the general population: A large population-based study in Dutch breast cancer patients

Marissa C. van Maaren, Robert F. Kneepkens, Joke Verbaan, Peter C. Huijgens, Valery E. P. P. Lemmens, Rob H. A. Verhoeven, Sabine Siesling

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objective Many cancer survivors are facing difficulties in getting a life insurance; raised premiums and declinatures are common. We generated a prediction model estimating the conditional extra mortality risk of breast cancer patients in the Netherlands. This model can be used by life insurers to accurately estimate the additional risk of an individual patient, conditional on the years survived. Methodology All women diagnosed with stage I-III breast cancer in 2005–2006, treated with surgery, were selected from the Netherlands Cancer Registry. For all stages separately, multivariable logistic regression was used to estimate annual mortality risks, conditional on the years survived, until 10 years after diagnosis, resulting in 30 models. The conditional extra mortality risk was calculated by subtracting mortality rates of the general Dutch population from the patient mortality rates, matched by age, gender and year. The final model was internally and externally validated, and tested by life insurers. Results We included 23,234 patients: 10,101 stage I, 9,868 stage II and 3,265 stage III. The final models included age, tumor stage, nodal stage, lateralization, location within the breast, grade, multifocality, hormonal receptor status, HER2 status, type of surgery, axillary lymph node dissection, radiotherapy, (neo)adjuvant systemic therapy and targeted therapy. All models showed good calibration and discrimination. Testing of the model by life insurers showed that insurability using the newly-developed model increased with 13%, ranging from 0%-24% among subgroups. Conclusion The final model provides accurate conditional extra mortality risks of breast cancer patients, which can be used by life insurers to make more reliable calculations. The model is expected to increase breast cancer patients’ insurability and transparency among life insurers.
Original languageEnglish
Article numbere0210887
JournalPLoS ONE
Volume14
Issue number1
DOIs
Publication statusPublished - 1 Jan 2019

Cite this

van Maaren, Marissa C. ; Kneepkens, Robert F. ; Verbaan, Joke ; Huijgens, Peter C. ; Lemmens, Valery E. P. P. ; Verhoeven, Rob H. A. ; Siesling, Sabine. / A conditional model predicting the 10-year annual extra mortality risk compared to the general population: A large population-based study in Dutch breast cancer patients. In: PLoS ONE. 2019 ; Vol. 14, No. 1.
@article{e72c21bba77f40e8a795da27d389d206,
title = "A conditional model predicting the 10-year annual extra mortality risk compared to the general population: A large population-based study in Dutch breast cancer patients",
abstract = "Objective Many cancer survivors are facing difficulties in getting a life insurance; raised premiums and declinatures are common. We generated a prediction model estimating the conditional extra mortality risk of breast cancer patients in the Netherlands. This model can be used by life insurers to accurately estimate the additional risk of an individual patient, conditional on the years survived. Methodology All women diagnosed with stage I-III breast cancer in 2005–2006, treated with surgery, were selected from the Netherlands Cancer Registry. For all stages separately, multivariable logistic regression was used to estimate annual mortality risks, conditional on the years survived, until 10 years after diagnosis, resulting in 30 models. The conditional extra mortality risk was calculated by subtracting mortality rates of the general Dutch population from the patient mortality rates, matched by age, gender and year. The final model was internally and externally validated, and tested by life insurers. Results We included 23,234 patients: 10,101 stage I, 9,868 stage II and 3,265 stage III. The final models included age, tumor stage, nodal stage, lateralization, location within the breast, grade, multifocality, hormonal receptor status, HER2 status, type of surgery, axillary lymph node dissection, radiotherapy, (neo)adjuvant systemic therapy and targeted therapy. All models showed good calibration and discrimination. Testing of the model by life insurers showed that insurability using the newly-developed model increased with 13{\%}, ranging from 0{\%}-24{\%} among subgroups. Conclusion The final model provides accurate conditional extra mortality risks of breast cancer patients, which can be used by life insurers to make more reliable calculations. The model is expected to increase breast cancer patients’ insurability and transparency among life insurers.",
author = "{van Maaren}, {Marissa C.} and Kneepkens, {Robert F.} and Joke Verbaan and Huijgens, {Peter C.} and Lemmens, {Valery E. P. P.} and Verhoeven, {Rob H. A.} and Sabine Siesling",
year = "2019",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0210887",
language = "English",
volume = "14",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

A conditional model predicting the 10-year annual extra mortality risk compared to the general population: A large population-based study in Dutch breast cancer patients. / van Maaren, Marissa C.; Kneepkens, Robert F.; Verbaan, Joke; Huijgens, Peter C.; Lemmens, Valery E. P. P.; Verhoeven, Rob H. A.; Siesling, Sabine.

In: PLoS ONE, Vol. 14, No. 1, e0210887, 01.01.2019.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - A conditional model predicting the 10-year annual extra mortality risk compared to the general population: A large population-based study in Dutch breast cancer patients

AU - van Maaren, Marissa C.

AU - Kneepkens, Robert F.

AU - Verbaan, Joke

AU - Huijgens, Peter C.

AU - Lemmens, Valery E. P. P.

AU - Verhoeven, Rob H. A.

AU - Siesling, Sabine

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective Many cancer survivors are facing difficulties in getting a life insurance; raised premiums and declinatures are common. We generated a prediction model estimating the conditional extra mortality risk of breast cancer patients in the Netherlands. This model can be used by life insurers to accurately estimate the additional risk of an individual patient, conditional on the years survived. Methodology All women diagnosed with stage I-III breast cancer in 2005–2006, treated with surgery, were selected from the Netherlands Cancer Registry. For all stages separately, multivariable logistic regression was used to estimate annual mortality risks, conditional on the years survived, until 10 years after diagnosis, resulting in 30 models. The conditional extra mortality risk was calculated by subtracting mortality rates of the general Dutch population from the patient mortality rates, matched by age, gender and year. The final model was internally and externally validated, and tested by life insurers. Results We included 23,234 patients: 10,101 stage I, 9,868 stage II and 3,265 stage III. The final models included age, tumor stage, nodal stage, lateralization, location within the breast, grade, multifocality, hormonal receptor status, HER2 status, type of surgery, axillary lymph node dissection, radiotherapy, (neo)adjuvant systemic therapy and targeted therapy. All models showed good calibration and discrimination. Testing of the model by life insurers showed that insurability using the newly-developed model increased with 13%, ranging from 0%-24% among subgroups. Conclusion The final model provides accurate conditional extra mortality risks of breast cancer patients, which can be used by life insurers to make more reliable calculations. The model is expected to increase breast cancer patients’ insurability and transparency among life insurers.

AB - Objective Many cancer survivors are facing difficulties in getting a life insurance; raised premiums and declinatures are common. We generated a prediction model estimating the conditional extra mortality risk of breast cancer patients in the Netherlands. This model can be used by life insurers to accurately estimate the additional risk of an individual patient, conditional on the years survived. Methodology All women diagnosed with stage I-III breast cancer in 2005–2006, treated with surgery, were selected from the Netherlands Cancer Registry. For all stages separately, multivariable logistic regression was used to estimate annual mortality risks, conditional on the years survived, until 10 years after diagnosis, resulting in 30 models. The conditional extra mortality risk was calculated by subtracting mortality rates of the general Dutch population from the patient mortality rates, matched by age, gender and year. The final model was internally and externally validated, and tested by life insurers. Results We included 23,234 patients: 10,101 stage I, 9,868 stage II and 3,265 stage III. The final models included age, tumor stage, nodal stage, lateralization, location within the breast, grade, multifocality, hormonal receptor status, HER2 status, type of surgery, axillary lymph node dissection, radiotherapy, (neo)adjuvant systemic therapy and targeted therapy. All models showed good calibration and discrimination. Testing of the model by life insurers showed that insurability using the newly-developed model increased with 13%, ranging from 0%-24% among subgroups. Conclusion The final model provides accurate conditional extra mortality risks of breast cancer patients, which can be used by life insurers to make more reliable calculations. The model is expected to increase breast cancer patients’ insurability and transparency among life insurers.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85060492123&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30677053

U2 - 10.1371/journal.pone.0210887

DO - 10.1371/journal.pone.0210887

M3 - Article

VL - 14

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 1

M1 - e0210887

ER -